Portfolio company Day One acquired by Servier

Summary by AI BETAClose X

International Biotechnology Trust PLC announced that its portfolio company, Day One Biopharmaceuticals, has agreed to be acquired by Servier for $2.5 billion in cash, with Day One shareholders receiving $21.50 per share, a 67% premium. Day One, which represents 1.8% of IBT's Net Asset Value as of March 5th, has developed the FDA-approved OJEMDA therapy for a specific type of childhood brain tumor. This acquisition is the first for IBT in 2026 and follows nine portfolio company acquisitions in 2025, indicating a continued trend of M&A activity in the biotech sector driven by pharmaceutical companies addressing patent cliffs. The updated valuation of IBT's holding in Day One will be reflected in its NAV report.

Disclaimer*

UK 100

Latest directors dealings